Idiopathic recurrent pericarditis – a new orphan autoinflammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis

Aim To analyze cases of idiopathic recurrent pericarditis (IRP) in the structure of pericardial diseases of various origins from patient visits to the Multidisciplinary Federal Center.
Material and methods A retrospective analysis of case records was performed for patients admitted to the V.A. Almazov National Medical Research Center from January 1, 2015 through January 1, 2020 for pericardial effusion of different etiologies.
Results For the study period, 4 981 new cases of pericardial damage of different etiologies were found. Among these cases, postpericardiotomy syndrome accounted for 4 360 cases and pericarditis for 621 cases. IRP was detected in 34 cases, which amounted to 5.4 %. Based on the study data, the estimated IRP prevalence in the Russian Federation can be 1.1 cases per 100 thousand population.
Conclusion IRP should be regarded as a new autoinflammatory disease, the prevalence of which borders on that of adult Still disease and should be addressed within the concept of orphan diseases. Current knowledge of the pathogenesis and data from recent studies demonstrated a great importance of interleukin-1 blockade as a leading mechanism for achieving remission. This has justified conduction of a randomized clinical study at the Center.

1. Kastner DL. Autoinflammation: Past, Present, and Future. In: Textbook of Autoinflammation. P. 3-15 [DOI: 10.1007/978-3-319-98605-0_1]. Hashkes PJ, Laxer RM, Simon A, editors -Cham: Springer International Publishing;2019. ISBN 978-3-319-98604-3

2. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror Autoinflammaticus: The Molecular Pathophysiology of Autoinflammatory Disease. Annual Review of Immunology. 2009;27(1):621–68. DOI: 10.1146/annurev.immunol.25.022106.141627

3. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nature Reviews Molecular Cell Biology. 2003;4(2):95–104. DOI: 10.1038/nrm1019

4. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation: Mechanism of NLRP3 inflammasome activation. Annals of the New York Academy of Sciences. 2014;1319(1):82–95. DOI: 10.1111/nyas.12458

5. U.S. Food and Drug Administration. Kineret - FDA prescribing information, side effects and uses. 2018. [Internet] Available at: https://www.drugs.com/pro/kineret.html

6. European Medicines Agency. Kineret (anakinra) European public assessment reports summary. 2018. [Internet] Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret

7. U.S. Food and Drug Administration. Ilaris (canakinumab) full prescribing information. 2016. Av. at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/BLA125319_858687lbl.pdf.

8. European Medicines Agency. Ilaris (canakinumab) European public assessment reports summary. 2017. [Internet] Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris

9. U.S. Food and Drug Administration. Arcalyst (rilonacept) full prescribing information. 2008. Av. at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf.

10. Kuemmerle-Deschner JB, Gautam R, George AT, Raza S, Lomax KG, Hur P. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrinassociated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open. 2020;6(2): e001227. DOI: 10.1136/rmdopen-2020-001227

11. Castañeda S, Atienza-Mateo B, Martín-Varillas JL, Serra LópezMatencio JM, González-Gay MA. Anakinra for the treatment of adult-onset Still’s disease. Expert Review of Clinical Immunology. 2018;14(12):979–92. DOI: 10.1080/1744666X.2018.1536548

12. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine. 2018;378(20):1908–19. DOI: 10.1056/NEJMoa1706314

13. Tombetti E, Mulè A, Tamanini S, Matteucci L, Negro E, Brucato A et al. Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020. Current Cardiology Reports. 2020;22(8):59. DOI: 10.1007/s11886-020-01308-y

14. Harapas CR, Steiner A, Davidson S, Masters SL. An Update on Autoinflammatory Diseases: Inflammasomopathies. Current Rheumatology Reports. 2018;20(7):40. DOI: 10.1007/s11926-018-0750-4

15. Milchert M, Makowska J, Brzezińska O, Brzosko M, WięsikSzewczyk E. Monogenic autoinflammatory diseases in adults – a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment. Reumatologia/Rheumatology. 2019;57(6):326–35. DOI: 10.5114/reum.2019.91298

16. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I et al. Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases. 2019;78(8):1025–32. DOI: 10.1136/ annrheumdis-2019-215048

17. Orphanet. The portal for rare diseases and orphan drugs. [Internet] Available at: https://www.orpha.net/consor/cgi-bin/index.php

18. Aronson JK. Rare diseases and orphan drugs. British Journal of Clinical Pharmacology. 2006;61(3):243–5. DOI: 10.1111/j.1365-2125.2006.02617.x

19. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921–64. DOI: 10.1093/eurheartj/ehv318

20. Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M et al. Colchicine as First-Choice Therapy for Recurrent Pericarditis: Results of the CORE (COlchicine for REcurrent pericarditis) Trial. Archives of Internal Medicine. 2005;165(17):1987–91. DOI: 10.1001/archinte.165.17.1987

21. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. The Lancet. 2014;383(9936):2232–7. DOI: 10.1016/S0140-6736(13)62709-9

22. Cacoub P, Marques C. Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. Heart. 2020;106(14):1046–51. DOI: 10.1136/heartjnl-2019-316481

23. Banteva M.N., Kuznetsova V.P., Rugol L.V. Main indicators of inpatient care in the russian federation in the dynamics for 2010-2016. Journal of New Medical Technologies. 2018; 5:90–7. DOI: 10.24411/2075-4094-2018-16214

24. Ota T, Higashi S, Suzuki H, Eto S. Increased serum ferritin levels in adult Still’s disease. The Lancet. 1987;329(8532):562–3. DOI: 10.1016/S0140-6736(87)90204-2

25. Myachikova V.Yu., Maslyansky A.L., Gaydukova I.Z., Novikova A.N., Karpova D.V., Shlyakhto E.V. Difficulties in diagnosis and treatment of adult-onset Still’s disease concurrent with pericardial effusion as a leading clinical manifestation. Modern Rheumatology Journal. 2016;10(1):31–6. DOI: 10.14412/1996-7012-2016-1-31-36

26. Karateev A.E., Nasonov E.L., Yakhno N.N., Ivashkin V.T., Chichasova N.V., Alekseeva L.I. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology Journal. 2015;9(1):4–23. DOI: 10.14412/1996-7012-2015-1-4-23

27. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research & Therapy. 2020;22(1):28. DOI: 10.1186/s13075-020-2120-7

28. Buchman AL. Side Effects of Corticosteroid Therapy. Journal of Clinical Gastroenterology. 2001;33(4):289–94. DOI: 10.1097/00004836-200110000-00006

29. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M et al. Effect of Anakinra on Recurrent Pericarditis Among Patients with Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906–12. DOI: 10.1001/jama.2016.15826